US FDA Staff Expresses Concerns Over Merck’s Chronic Cough Drug Efficacy
Ahead of an upcoming meeting of independent experts, the U.S. health regulator’s staff has raised doubts about the adequacy of data supporting Merck’s chronic cough drug’s meaningful benefits, according to documents released on Wednesday. Merck’s shares dropped nearly 1 percent to $101.2 in afternoon trade following the news. This concern emerged after Merck submitted additional …
US FDA Staff Expresses Concerns Over Merck’s Chronic Cough Drug Efficacy Read More »